Background
==========

In Italy, about 600,000 patients are affected by ulcers of neuro-vascular origin, 50% of which are represented by venous chronic ulcers, inveterate and painful. (Surveying of the Ministry of Health -- 2001). Of these approximately 60% are constituted by elderly patients.

Objective
=========

To verify the results obtained in 240 elderly patients, age ranged between 70 and 92 years-old (66.9% females -- 31.1% males), affected with ulcers of the lower limbs, treated by cultivated autografts of skin, from April 2001 to August 2008.

Materials and methods
=====================

The biotechnologies are based on the drawing of a small fragment of skin (2--3 cmq), at the elbow. Subsequently, the skin fragment is sent to a specialized laboratory in cellular cultivated membrane, where it is divided into its two essential components: dermatocytes and cheratinocytes.

These, after having been separated, centrifugated and implanted on an adapted medium which consists of modified three-dimensional jaluronic acid, develop in vitro an extended layer of tissue (dimensions 100--200 cmq), which then will be grafted separately (after 4 weeks from the biopsy) on the surface of the ulcer.

For the correct execution of such procedure are necessary four surgical steps, in sequence:

1\. The debridement of the ulcer, the elasto-compressive bendage of the leg and the drawing of the skin.

2\. The grafting of the layer of dermatocytes (called Hyalograft 3D) after 22--30 days.

3\. The grafting of the layer of cheratinocytes (called Laserskin), after others 22--30 days.

4\. The surgical treatment of the venous or arterial insufficiency after 1--10 months.

Results
=======

We have performed a total of 520 autografts (234 dermatocytes -- 286 cheratinocytes). Approximately half of the ulcers treated, were venous chronic ulcers, inveterate and painful secondary to chronic venous insufficiency of the lower limbs and/or post-thrombotic syndrome.

A clinical follow-up was performed on 186 out of the 240 cases, medially for 26 months (ranging between 3 months -- 7 years and 4 months). In reference our experience, on the 240 cases treated, we have obtained 207 cases (86.25%) of complete healing, 27 cases (11.25%) of partial healing, with a reduction of the ulcerated area \>50%, 6 cases (2.5%) of therapeutic failure, with a reduction of the ulcerated area \<50%, 2 cases (0.83%) of amputations and 18 cases (7.5%) of relapses. The mean time for the complete closing of the ulcers has been of 13.4 weeks calculated by the date of the first graft (range 4.1--33.2 weeks). Data on line to the more recent literature, in which is described a percentage of 95% of good clinical results (ulcers partially and completely closed) and stable in the time.

Conclusion
==========

The advantages of this surgical method, by now universally accepted, are, therefore, of remarkable clinical and social relief and we can summarize them as follows:

1\. The proved clinical effectiveness;

2\. The security of the biotechnological procedure in terms of microbiological pollution of the samples;

3\. The long-lasting results;

4\. A positive relationship between cost and benefits.

In addition, we completely agree in asserting that such a procedure is easy and fast in execution, well-tolerated and able to replace the traditional and very more complex surgical methods.
